結城 敏志

結城 敏志

助教

学歴

1993年3月
釧路湖陵高等学校卒業
1999年3月
弘前大学医学部卒業
2007年3月
北海道大学大学院医学研究科病態制御学専攻医学博士課程終了

職経

1999年6月
北海道大学医学部附属病院 研修医
2000年4月
NTT東日本札幌病院 研修医
2001年4月
釧路労災病院内科 医師
2002年4月
網走厚生病院内科 医師
2006年4月
北海道大学病院第3内科 医員
2008年4月
北海道大学病院第3内科 助教
2012年4月
北海道大学病院消化器内科 助教

専門分野

  • 臨床腫瘍学
  • 消化器腫瘍学

所属学会・資格

  • 日本内科学会 認定内科医
  • 日本癌治療学会
  • 日本臨床腫瘍学会 がん薬物療法専門医・指導医・評議員
  • 日本消化器病学会
  • 日本胃癌学会
  • 日本消化器内視鏡学会
  • 日本がん予防学会
  • 米国臨床腫瘍学会(ASCO)
  • 欧州臨床腫瘍学会(ESMO)
  • 日本がん治療認定医機構 がん治療認定医・暫定教育医

受賞歴

  • 2013年 Asia Pacific Cancer Conference:Young Investigator's Award

業績(英文のみ)

  1. Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y.
    An open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
    Cancer Sci. 2015. In press.
  2. Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, Sogabe S, Tateyama M, Hatanaka K, Tsuji Y, Nakamura M, Konno J, Yamamoto F, Onodera M, Iwai K, Sakata Y, Abe R, Oba K, Sakamoto N.
    Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.
    Future Oncol. 11(4) : 617-27, 2015.
  3. Komatsu Y, Yoshino T, Yamazaki K, Yuki S, Machida N, Sasaki T, Hyodo I, Yachi Y, Onuma H, Ohtsu.
    A Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Invest New Drugs. 32(3) : 473-80, 2014.
  4. Shitara K, Yuki S, Tahahari D, Nakamura M, Kondo C, Tsuda T, Kii T, Tsuji Y, Utsunomiya S, Ichikawa D, Hosokawa A, Ishiguro A, Sakai D, Hironaka S, Oze I, Matsuo K, Muro K.
    Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
    Br J Cancer. 110(2): 271-7, 2014.
  5. Bando H, Yoshino T, Shinozaki E, Nishina T, Yamazaki K, Yamaguchi K, Yuki S, Kajiura S, Fujii S, Yamanaka T, Tsuchihara K, Ohtsu A.
    Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.
    BMC Cancer. 13(1): 405, 2013.
  6. Shitara K, Yuki S, Yamazaki K, Naito Y, Fukushima H, Komatsu Y, Yasui H, Takano T, Muro K.
    Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
    Cancer Res Clin Oncol. 139(4): 595-603, 2013.
  7. Nakatsumi H, Komatsu Y, Yuki S, Sogabe S, Tateyama M, Muto S, Kudo M, Kato K, Miyagishima T, Uebayashi M, Meguro T, Oba K, Asaka M.
    Optimal Dose Period for Indisetron Tablets for Preventing Chemotherapy-Induced Nausea and Vomiting with Modified FOLFOX6: A Randomized Pilot Study.
    Chemotherapy. 58(6): 439-444, 2013.
  8. Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S, Yamazaki K, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Ohtsu A.
    Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab + Irinotecan.
    Jpn J Clin Oncol. 42(12): 1146-51, 2012.
  9. Morita S, Oizumi S, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y, Inada M, Yuki S, Kiyota N, Mitsuma A, Sawaki M, Tanii H, Kimura J, Ando Y.
    Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.
    Invest New Drugs. 30(5): 1950-7, 2012.
  10. Komatsu Y, Yuki S, Sogabe S, Fukushima H, Nakatsumi H, Kobayashi Y, Iwanaga I, Nakamura M, Hatanaka K, Miyagishima T, Kudo M, Munakata M, Meguro T, Tateyama M, Sakata Y.
    Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
    Acta Oncol. 51(7): 867-72, 2012.
  11. Shitara K, Yuki S, Yoshida M, Takahari D, Utsunomiya S, Yokota T, Sato Y, Inaba Y, Tajika M, Kawai H, Yamaura H, Kato M, Yamazaki K, Komatsu Y, Muro K.
    Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Invest New Drugs. 30(2): 787-93, 2012.
  12. Komatsu Y, Yuki S, Sogabe S, Fukushima H, Iwanaga I, Kudo M, Tateyama M, Meguro T, Uebayashi M, Saga A, Sakata Y, Asaka M.
    Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
    Oncology. 80(1-2): 70-5, 2011.
  13. Shitara K, Ura T, Matsuo K, Takahari D, Yokota T, Yuki S, Yoshida M, Utsunomiya S, Sato Y, Yamaura H, Kato M, Inaba Y, Tajika M, Kawai H, Yamazaki K, Komatsu Y, Muro K.
    Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
    Eur J Cancer. 47(18): 2673-80, 2011.
  14. Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M.
    Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Jpn J Clin Oncol. 41(4): 490-7, 2011.
  15. Shitara K, Oze I, Mizota A, Kondo C, Nomura M, Yokota T, Takahari D, Ura T, Yuki S, Komatsu Y, Matsuo K, Muro K.
    Randomized phase II study comparing dose escalated weekly paclitaxel vs.
    standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
    Jpn J Clin Oncol. 41(2): 287-90, 2011.
  16. Komatsu Y, Yuki S, Fuse N, Kato T, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Sakata Y, Asaka M.
    Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
    Adv Ther. 27(7): 483-92, 2010.
  17. Shitara K, Yokota T, Takahari D, Shibata T, Ura T, Komatsu Y, Yuki S, Yoshida M, Takiuchi H, Utsunomiya S, Yatabe Y, Muro K.
    Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
    Jpn J Clin Oncol. 40(7): 699-701, 2010.
  18. Yuki S, Komatsu Y, Fuse N, Kato T, Miyagishima T, Kudo M, Watanabe M, Tateyama M, Kunieda Y, Wakahama O, Sakata Y, Asaka M.
    Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.
    Clin Drug Investig. 30(4): 243-9, 2010.
  19. Shitara K, Komatsu Y, Yuki S, Munakata M, Muto O, Shimaya S, Sakata Y.
    Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer.
    Oncology. 75(1-2): 67-70, 2008.
  20. Komatsu Y, Takei M, Yuki S, Fuse N, Furukawa S, Kato T, Takeda H, Kato M, Asaka M.
    Treatment of a Gilbert's syndrome patient with irinotecan, leucovorin and 5-fluorouracil.
    J Chemother. 17(1): 111-4, 2005.
  21. Komatsu Y, Yuki S, Fuse N, Takei M, Kato T, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Ohizumi H, Watanabe M, Akita H, Sakata Y, Asaka M.
    Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
    Jpn J Clin Oncol. 35(2): 88-9, 2005.
(国際学会、筆頭演者のみ)
  1. Yuki S, Yoshino T, Tsuchihara K, Shinozaki E, Muro K, Nishina T, Yamaguchi K, Akagi K, Yamazaki K, Yamanaka T, Nomura S, Fujii S, Esumi H, Abe Y, Ohtsu A.
    Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).
    2015 ASCO Annual Meeting. Chicago, May 29-Jun 2, 2015.
  2. Yuki S, Nakatsumi H, Hayashi H, Fukushima H, Kato T, Meguro T, Nakamura M, Iwanaga I, Eto K, Sato A, Okuda H, Oba A, Miyagishima T, Muto O, Yabusaki S, Miyamoto N, Kudo K, Sakamoto N, Sakata Y, Komatsu Y.
    Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.
    2015 Gastrointestinal Cancers Symposium. San Francisco, Jan 15-17, 2015.
  3. Yuki S, Komatsu Y, Harada K, Fukushima H, Sasaki T, Kobayashi Y, Tsuji Y, Naruse H, Okuda H, Takahashi Y, Hosokawa A, Konno J, Eto K, Kudo M, Kawamoto Y, Sonoda N, Sato Y, Uebayashi M, Kato T, Onodera M, Ohta T, Sakata Y.
    Analysis of Glasgow Prognostic Score (GPS) in KRAS Exon2 wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.
    16th World Congress on Gastrointestinal Cancer. Barcelona, Jun 25-28, 2014.
  4. Yuki S, Komatsu Y, Fukushima H, Sasaki T, Kobayashi Y, Harada K, Dazai M, Sogabe S, Miyagishima T, Ichiguro A, Takahata T, Sato A, Kudo M, Kato S, Kato K, Iwanaga I, Ehira N, Uebayashi M, Sakata Y.
    Phase II trial of S-1 plus split Cisplatin (SSP) in patients with advanced gastric cancer (HGCSG0702) : Final report.
    2014 Gastrointestinal Cancers Symposium. San Francisco, Jan 16-18, 2014.
  5. Yuki S, Komatsu Y, Fukushima H, Sasaki T, Kobayashi Y, Harada K, Amano T, Nakamura M, Kudo M, Tateyama M, Hatanaka K, Saitoh S, Miyagishima T, Kato T, Kawamoto Y, Takagi T, Iwanaga I, Miyashita K, Onodera M, Sakata Y.
    The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Including multivariate analysis of two phase II studies.
    2014 Gastrointestinal Cancers Symposium. San Francisco, Jan 16-18, 2014.
  6. Yuki S, Komatsu Y, Fukushima H, Doi A, Tsuji Y, Hatanaka K, Okuda H, Fujikawa K, Watanabe Y, Hosokawa A, Amano T, Eto K, Kudo M, Akakura N, Munakata M, Tateyama M, Sato Y, Miyagishima T, Uebayashi M, Sakata Y.
    Analysis of K?hne's prognostic index in KRAS wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.
    22nd Asia Pacific Cancer Conference. Tianjin, Oct 31-Nov 2, 2013.
  7. Yuki S, Komatsu Y, Tsuji Y, Hatanaka K, Okuda H, Fujikawa K, Watanabe Y, Hosokawa A, Amano T, Sakata Y.
    Analysis of Kohne's prognostic index in KRAS wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.
    European Cancer Congress 2013. Amsterdam, Sep 27-Oct 1, 2013.
  8. Yuki S, Komatsu Y, Fukushima H, Sasaki T, Amano T, Miyagishima T, Hatanaka K, Nakamura M, Tateyama M, Sakata Y.
    Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer (mCRC) - Final analysis - : Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.
    2013 Gastrointestinal Cancers Symposium. San Francisco, Jan 24-26, 2013.
  9. Yuki S, Shitara K, Takahari D, Nakamura M, Kondo C, Tsuda T, Kii T, Tsuji Y, Oze I, Muro K.
    Preliminary safety data from a randomized phase II study comparing dose-escalated weekly paclitaxel versus standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
    ESMO 2012 Congress. Vienna, Sep 28-Oct 02, 2012.
  10. Yuki S, Komatsu Y, Miyagishima T, Kato T, Hatanaka K, Nakamura M, Kudo M, Akakura N, Tateyama M, Sakata Y.
    Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab(IRIS/Bev) in Patients with Metastatic Colorectal Cancer -Updated analysis-. Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.
    2012 ASCO Annual Meeting. Chicago, Jun 1-5, 2012.
  11. Yuki S, Komatsu Y, Kawamoto Y, Tsuji Y, Naruse H, Hosokawa A, Kusumi T, Ishiguro A, Saito S, Sakata Y.
    Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients: The HGCSG0901 Study - Analysis of after Cetuximab refractory -.
    2012 Gastrointestinal Cancers Symposium. San Francisco, Jan 19-21, 2012.
  12. Yuki S, Komatsu Y, Kogawa T, Hatanaka K, Kusumi T, Fujikawa K.
    Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients: The HGCSG0901 Study - Analysis of some predictive markers -.
    21st Asia Pacific Cancer Conference. Kuala Lumpur, Nov 10-12, 2011.
  13. Yuki S, Nakatsumi H, Tateyama M, Uehata Y, Kudo M, Kato K, Miyagishima T, Uebayashi M, Asaka M, Komatsu Y.
    The optimal dose period of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV) induced by mFOLFOX6: an exploratory trial -HGCSG0703-.
    2011 Gastrointestinal Cancers Symposium. San Francisco, Jan 20-22, 2011.
  14. Yuki S, Shitara K, Yoshida M, Takahari D, Utsunomiya S, Yokota T, Sato Y, Tajika M, Muro K.
    Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Wild-type KRAS Metastatic Colorectal cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines.
    2011 Gastrointestinal Cancers Symposium. San Francisco, Jan 20-22, 2011.
  15. Yuki S, Komatsu Y, Sogabe S, Iwanaga I, Kudo M, Miyagishima T, Nakamura M, Hatanaka K, Asaka M, Sakata Y.
    Phase II Study of Combination With Irinotecan and S-1(IRIS) for Inoperable Recurrent Advanced Colorectal Cancer(HGCSG0302).
    Final analysis.
    2009 Gastrointestinal Cancers Symposium. San Francisco, Jan 15-17, 2009.
  16. Yuki S, Komatsu Y, Machida N, Ozasa M, Nishi K, Miyagishima T, Kato T, Nakamura M, Asaka M, Sakata Y.
    Phase II Study of Combination With Irinotecan and S-1(IRIS) for Inoperable Recurrent Advanced Colorectal Cancer(HGCSG0302).
    Safety analysis.
    The European Cancer Conference (ECCO14). Barcelona, Sep 23-27, 2007.
  17. Yuki S, Komatsu Y, Fuse N, Tateyama M, Nishi K, Kato T, Kudo M, Miyagishima T, Asaka M, Sakata Y.
    Phase I/II study of docetaxel, cisplatin and 5-fluorouracil (TPF) as first-line chemotherapy in Japanese patients with advanced esophageal cancer.
    2006 Gastrointestinal Cancers Symposium. San Francisco, Jan 26-28, 2006.